Recently, a lot of attention has been focused on Swedish tech companies like $SIVE. However, one
sector that has been overlooked and left in the shadows is Scandinavian biotech. Specifically,
Cereno Scientific is a Swedish company that is in an exciting phase ahead of a potential revaluation
and deal.
Posting this as a quick DD-style reminder for anyone looking at undervalued biotech with multiple near term triggers.
Attached is a pitch deck for anyone who wants the full overview.
Cereno Scientific is currently trading at a market cap of roughly \*\*\\\~$160–200M range\*\*, which looks extremely small when you put it next to what the market has already paid for comparable assets in the same therapeutic area.
The most relevant benchmark here is \*\*Sotatercept (Winrevair / Acceleron asset)\*\*, which was acquired in a deal valuing it at roughly \*\*\\\~$7B+\*\* after mid stage data and strong PAH market validation.
Even using conservative assumptions, that puts Cereno at a \*\*fraction of the valuation of a single comparable asset\*\*, despite operating in the same high value PAH space with additional pipeline optionality.
\*\*Why people are watching this closely:\*\*
There are multiple \*\*near term catalysts and inflection points\*\* stacking up:
Ongoing and upcoming clinical readouts (Phase IIb progression is a key value driver)
Potential partnership / licensing discussions
Expansion optionality across fibrosis and thrombosis related indications
Increasing visibility at medical conferences and institutional interest
Continued clinical differentiation narrative around safety + disease modifying potential
\*\*The core bull argument in one line:\*\*
If Sotatercept was effectively “validated and priced” by the market at multi-billion level post Phase II, then Cereno sitting at \\\~160M market cap is essentially the asymmetric version of the same trade \*if the clinical trajectory continues to hold\*.
